Conavi Medical Raises C$10 Million in Public Offering | Lucid Diligence Brief

Conavi Medical’s C$10M Financing Puts Novasight U.S. Adoption and Funding Runway in Focus.

Professional audiences only. Not investment research or advice. UK readers: for persons under Article 19(5) or Article 49(2)(a)–(d) of the Financial Promotion Order 2005. Others should not act on this communication.

Dive deeper

Seven questions, 60-second thesis frame.

What changed, and when

Conavi Medical closed a C$10.0 million public offering on 12 Aug 2026, issuing 34.5 million common shares plus 15.5 million effectively equity-like pre-funded warrants, 50.0 million securities in total, at C$0.20/C$0.19999. Net proceeds are earmarked principally for the U.S. limited market release of its FDA-cleared Novasight Hybrid IVUS-OCT system, plus working capital. (Conavi closing announcement, Stockwatch coverage)

The key wrinkle is size, not regulatory risk. Conavi had marketed a C$10–15 million deal but closed at the C$10 million minimum. Agents received C$450,864 cash plus 2.25 million two-year compensation options exercisable at C$0.20. (Pricing announcement, Conavi closing announcement)

60-second thesis frame

The financing converts Conavi’s diligence question from “can it reach FDA clearance?” to “can C$10 million produce enough U.S. adoption evidence before another financing becomes necessary?” The FDA made its substantially-equivalent determination for next-generation Novasight on 17 Apr 2026, although Conavi publicly announced clearance on 20 Apr, so the apparent date discrepancy is simply FDA decision date versus company announcement date. (FDA 510(k) Premarket Notification, K252945, Cardiovascular Interventions Today)

The clinical backdrop is favourable because the 2025 ACC/AHA ACS guideline elevated intravascular imaging guidance during PCI to a Class 1 recommendation, but guideline support does not automatically give a small entrant hospital access against established IVUS and OCT franchises. (American College of Cardiology, TCTMD)

Financial execution is therefore central. Conavi reported only C$0.3 million revenue and a C$7.5 million net loss for the six months ended 31 Mar 2026, with C$4.5 million cash at period end. A further C$1.25 million Ontario milestone was received in June before this financing. (Fiscal Q2 2026 results, Conavi investor information)

The seven diligence questions

Clinical

• Does simultaneous IVUS-OCT generate enough incremental decision value to change cath-lab behaviour, rather than merely combining two already validated modalities? Novasight can provide simultaneous, co-registered IVUS and OCT imaging in one pullback, but the commercial proof still needs to come from physician use and workflow. (Cardiovascular Interventions Today)
• What evidence will persuade hospitals that hybrid imaging improves outcomes, contrast use or procedure economics enough to justify switching? Class 1 guideline support applies to intravascular imaging broadly, not specifically to Conavi’s hybrid implementation. (American College of Cardiology)

Payer or Access

• Can Conavi sell using existing hospital reimbursement economics, or will hybrid imaging require a stronger health-economic argument to overcome capital-budget resistance?
• Who pays for the incremental hybrid capability in practice, hospital, cath lab or payer, and does reimbursement capture enough value to support catheter pricing and gross margin?

Ops or Adoption

• What does a successful limited market release actually mean by year-end: systems placed, activated accounts, procedures per system, repeat catheter orders, or reference sites? Conavi says current launch work includes manufacturing scale-up, inventory, physician training and engagement with selected U.S. centres. (Fiscal Q2 2026 results)

Competitive

• Can hybrid IVUS-OCT overcome incumbency rather than compete on technical novelty alone? Established competitors already sell dedicated IVUS or OCT platforms and have materially larger cath-lab commercial infrastructures. (TCTMD guideline coverage)

Team or Cap table

• How much adoption evidence must management generate before the next financing, and on what dilution assumptions? The current round adds 50.0 million common-share equivalents before agent options, while the deal closed at the bottom of its marketed C$10–15 million range. (Pricing announcement, Conavi closing announcement)

Red flags

• Commercial launch remains capital-intensive before meaningful product revenue is visible. Six-month revenue to 31 Mar 2026 was C$0.3 million against a C$7.5 million net loss. (Fiscal Q2 2026 results)
• The financing stopped at the minimum marketed size. Failure to turn this C$10 million into credible placements, utilization and repeat disposable revenue would raise the probability of another dilutive raise. (Pricing announcement)
• Product-quality execution deserves explicit monitoring. FDA records show a 2025 Class I recall of first-generation Novasight catheters related to potential sheath detachment caused by manufacturing/process-control issues. That does not establish a problem with the new K252945 system, but recurrence would be a meaningful falsifier of the commercialization thesis. (FDA recall record)

Next catalyst

H2 2026: first measurable evidence from the Novasight U.S. limited market release, particularly named reference centres, system placements, first procedures and repeat catheter utilization. Management has explicitly targeted H2 2026 for launch activities. (Fiscal Q2 2026 results, Cardiovascular Interventions Today)

FAQ

What exactly changed with Conavi Medical’s C$10 million public-offering announcement on 12 Aug 2026?

Conavi completed a C$10 million financing comprising 34,500,775 common shares and 15.5 million pre-funded warrants. The company says proceeds will fund the limited U.S. market release of Novasight Hybrid plus working capital and general corporate purposes. (Conavi closing announcement, Stockwatch coverage)

Why does Conavi Medical’s C$10 million financing on 12 Aug 2026 matter after Novasight already received FDA clearance?

FDA clearance removes a major regulatory hurdle but does not establish commercial adoption. The capital is intended to finance manufacturing, inventory, training and deployment needed to turn the regulatory milestone into U.S. clinical use and recurring disposable demand. (FDA 510(k) Premarket Notification, Fiscal Q2 2026 results)

How dilutive was Conavi Medical’s C$10 million offering announced as closed on 12 Aug 2026?

The transaction created 50,000,775 new common-share equivalents, because the 15.5 million pre-funded warrants have a C$0.00001 exercise price and no expiry. Agents also received 2,254,365 compensation options exercisable at C$0.20 through 12 Aug 2028. (Conavi closing announcement)

What clinical and regulatory evidence supports the commercialization story behind Conavi Medical’s 12 Aug 2026 financing?

The FDA found next-generation Novasight substantially equivalent under 510(k) K252945 on 17 Apr 2026. Separately, the 2025 U.S. ACS guideline elevated intravascular imaging during relevant PCI procedures to a Class 1 recommendation, which supports the modality category but does not specifically endorse Conavi over competing platforms. (FDA 510(k) Premarket Notification, American College of Cardiology, TCTMD)

What should investors watch next after Conavi Medical closed the C$10 million offering on 12 Aug 2026?

The most decision-relevant evidence is likely to be operational rather than another regulatory milestone: hospital placements, first procedures, utilization per installed system and repeat catheter purchasing during H2 2026. Those metrics would test whether Conavi can translate FDA clearance and guideline tailwinds into repeatable commercial adoption. (Fiscal Q2 2026 results, Cardiovascular Interventions Today)

Publisher / Disclosure

Publisher: LucidQuest Ventures Ltd. Produced: 13 Aug 2026, 07:05 London. Purpose: general and impersonal information. Not investment research or advice, no offer or solicitation, no suitability assessment. UK: directed at investment professionals under Article 19(5) and certain high-net-worth entities under Article 49(2)(a)–(d) of the Financial Promotion Order 2005. Others should not act on this. Sources and accuracy: public sources believed reliable, provided “as is,” may change without notice. No duty to update. Past performance is not reliable. Forward-looking statements carry risks. Methodology: questions-first framework using public sources. No conflicts. Authors do not hold positions unless stated. © 2026 LucidQuest Ventures Ltd.

Entities / Keywords

Conavi Medical; CNVI; CNVIF; Novasight Hybrid; IVUS; OCT; hybrid IVUS-OCT; intravascular imaging; PCI; coronary intervention; FDA; K252945; 510(k); ACC; AHA; SCAI; ACS; cath lab; Bloom Burton Securities; TSX Venture Exchange; OTCQB; Ontario Life Sciences Scale-Up Fund; C$10 million offering; pre-funded warrants; commercialization; limited market release; hospital adoption; catheter utilization; reimbursement; manufacturing scale-up; United States; Canada